Comparative Efficacy and Cost of Asthma Care in Children with Asthma Treated with Fluticasone Propionate and Montelukast

Journal of Pediatrics

Volumn 150, Issue 2, 2007, Pages 162-167

  Stempel, David A ^a   Kruzikas, Denise T ^a   Manjunath, Ranjani ^a  

^a Infomed Northwest   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE DERIVATIVE; MONTELUKAST;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; ASTHMA; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; ODDS RATIO; PROBABILITY; QUINOLINES; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846341811     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.10.069     Document Type: Article

References (30)

1. National Asthma Education and Prevention Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma update on selected topics, 2002. J Allergy Clin Immunol 110 (2002) s141-s219
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication 02-3659, issued January 1995, updated 2002; management segment (chap 7) updated 2005. Available at www.ginasthma.org. Accessed December 1, 2005.
3. Wennergren G., Kristjánsson S., and Stannegård I.L. Decrease in hospitalizations for treatment of childhood asthma with increased use of anti-inflammatory treatment, despite an increase in the prevalence of asthma. J Allergy Clin Immunol 97 (1996) 742-748
4. Donahue J.G., Weiss S.T., Livingston J.M., Goetsch M.A., Greineder D.K., and Platt R. Inhaled corticosteroids and the risk of hospitalization for asthma. JAMA 227 (1997) 887-891
5. Suissa S., Ernst P., and Kezouh A. Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma. Thorax 57 (2002) 880-884
6. Ducharme F.M., and Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2 (2005) Accessed January 31, 2006 through DVID
7. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
8. Zeiger R.S., Szefler S.J., Phillips B.R., Schatz M., Martinez F.D., Chinchilli V.M., et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117 (2006) 45-52
9. Ostrum N.K., Decotis B.A., Lincourt W.R., Edwards L.D., Hanson K.M., Carranza Rosenzweig J.R., et al. Comparative safety and efficacy of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 147 (2005) 213-220
10. Garcia Garcia M.L., Wahl U., Gilles L., Swern A., Tozzi C.A., and Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14- year-old patients with mild asthma: the MOSAIC study. Pediatrics 116 (2005) 360-369
11. Stempel D.A., Mauskopf J., McLaughlin T., Yazdani C., and Stanford R.H. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Resp Med 95 (2001) 227-234
12. Stempel D.A., Pinto L., and Stanford R.H. The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist. J Allergy Clin Immunol 110 (2002) 39-41
13. Orsini L., Limpa-Amara S., Crown W.H., and Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 92 (2004) 523-529
14. Allen-Ramey F.C., Duong P.T., Riedel A.A., Markson L.E., and Weiss K.B. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol 93 (2004) 373-380
15. Sin D.D., Man J., Sharpe H., Gan W.Q., and Paul Man S.F. Pharmacological management to reduce exacerbations in adults with asthma. JAMA 292 (2004) 367-376
16. Mannino D.M., Homa D.M., Akinbami L.J., Moorman J.E., Gwynn C., and Redd S.C. Surveillance for asthma: United States, 1980-1999. MMWR 51 (2002) 1-14
17. Blais L., Ernst P., Biovin J.-F., and Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 158 (1998) 126-132
18. Stempel D.A., McLaughlin T.P., Stanford R.H., and Fuhlbrigge A.L. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol 115 (2005) 935-939
19. Suissa S., Ernst P., and Kezouh A. Regular use of inhaled corticosteroids and the long-term prevention of hospitalization for asthma. Thorax 57 (2002) 880-884
20. Schatz M., Cook E.F., Nakahiro R., and Petitti D. Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immun 111 (2003) 503-508
21. Lanes S.F., Garcia Rodriquez L.A., and Huerta C. Respiratory medications and risk of asthma death. Thorax 57 (2002) 683-687
22. Pendergraft T.B., Stanford R.H., Beasley R., Stempel D.S., and McLaughlin T. Seasonal variation in asthma-related hospital and intensive care unit admissions. J Asthma 42 (2005) 265-271
23. Johnston N.W., Johnston S.L., Duncan J.M., Greene J.M., Kebadze T., Keith P.K., et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 115 (2005) 132-138
24. Luskin A., Bukstein D., Sazonov Kocevar V., and Yin D.D. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy. Ann Allergy Asthma Immunol 95 (2005) 129-136
25. Kelly H.W. Inhaled corticosteroids versus leukotriene receptor antagonists as first-line therapy for mild persistent asthma in children?. Pediatr Asthma Allergy Immunol 18 (2005) 259-263
26. Stempel D.A., Meyer J.W., Stanford R.H., and Yancey S.W. One year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 107 (2001) 94-98
27. Stempel D.A., Mauskopf J., McLaughlin T., Yazdani C., and Stanford R.H. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Resp Med 95 (2001) 227-234
28. Allen-Ramey F.C., Anstatt D.T., Sajjan S.G., and Markson L.E. Asthma-related health care resource use among patients starting fluticasone or montelukast therapy. Pharmacotherapy 25 (2005) 1752-1760
29. Benson K., and Hartz A.J. A comparison of observational studies and randomized clinical trials. New Engl J Med 342 (2000) 1887-1892
30. Concato J., Shah N., and Horowitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 342 (2000) 1878-1886